within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J04A_DrugsForTreatmentOfTuberculosis.J04AB02_Rifampicin;
model Rifampicin 
   extends Pharmacolibrary.Drugs.ATC.J.J04AB02;

  annotation(Documentation(
    info ="<html><body><p>Rifampicin is a broad-spectrum antibiotic used primarily for the treatment of tuberculosis and leprosy. It works by inhibiting bacterial DNA-dependent RNA polymerase and is a key component of first-line anti-tuberculosis therapy. Rifampicin is currently approved and widely used in clinical practice.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult healthy volunteers following single oral administration of rifampicin.</p><h4>References</h4><ol><li><p>Abulfathi, AA, et al., &amp; Reuter, H (2019). Clinical Pharmacokinetics and Pharmacodynamics of Rifampicin in Human Tuberculosis. <i>Clinical pharmacokinetics</i> 58(9) 1103–1129. DOI:<a href=&quot;https://doi.org/10.1007/s40262-019-00764-2&quot;>10.1007/s40262-019-00764-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/31049868/&quot;>https://pubmed.ncbi.nlm.nih.gov/31049868</a></p></li><li><p>Niemi, M, et al., &amp; Kivistö, KT (2003). Pharmacokinetic interactions with rifampicin : clinical relevance. <i>Clinical pharmacokinetics</i> 42(9) 819–850. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200342090-00003&quot;>10.2165/00003088-200342090-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12882588/&quot;>https://pubmed.ncbi.nlm.nih.gov/12882588</a></p></li><li><p>Wasserman, S, et al., &amp; Wilkinson, RJ (2021). Plasma Pharmacokinetics of High-Dose Oral versus Intravenous Rifampicin in Patients with Tuberculous Meningitis: a Randomized Controlled Trial. <i>Antimicrobial agents and chemotherapy</i> 65(8) e0014021–None. DOI:<a href=&quot;https://doi.org/10.1128/AAC.00140-21&quot;>10.1128/AAC.00140-21</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33972248/&quot;>https://pubmed.ncbi.nlm.nih.gov/33972248</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Rifampicin;
